Indraprastha Medical Corporation Limited
Indraprastha Medical Corporation Limited (INDRAMEDCO.BO) Stock Competitors & Peer Comparison
See (INDRAMEDCO.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INDRAMEDCO.BO | ₹400.00 | +3.94% | 34.1B | 18.62 | ₹19.96 | +1.21% |
| APOLLOHOSP.BO | ₹7,288.60 | -3.44% | 1.1T | 59.28 | ₹125.30 | +0.26% |
| APOLLOHOSP.NS | ₹7,293.00 | -3.39% | 1.1T | 59.21 | ₹125.31 | +0.26% |
| MAXHEALTH.NS | ₹955.35 | -2.03% | 936.4B | 66.23 | ₹14.53 | +0.16% |
| MAXHEALTH.BO | ₹958.85 | -1.65% | 935.8B | 66.18 | ₹14.53 | +0.16% |
| FORTIS.NS | ₹792.50 | -2.66% | 600.2B | 62.50 | ₹12.72 | +0.13% |
| FORTIS.BO | ₹798.20 | -1.89% | 599.9B | 62.52 | ₹12.71 | +0.13% |
| ASTERDM.BO | ₹688.35 | +3.30% | 347.1B | 105.26 | ₹6.38 | +0.75% |
| ASTERDM.NS | ₹687.60 | +2.93% | 346.3B | 104.20 | ₹6.43 | +0.75% |
| NH.BO | ₹1,636.00 | -0.03% | 326.1B | 38.63 | ₹41.56 | +0.28% |
Stock Comparison
INDRAMEDCO.BO vs APOLLOHOSP.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, APOLLOHOSP.BO has a market cap of 1.1T. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while APOLLOHOSP.BO trades at ₹7,288.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas APOLLOHOSP.BO's P/E ratio is 59.28. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to APOLLOHOSP.BO's ROE of +0.21%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to APOLLOHOSP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check APOLLOHOSP.BO's competition here
INDRAMEDCO.BO vs APOLLOHOSP.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, APOLLOHOSP.NS has a market cap of 1.1T. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while APOLLOHOSP.NS trades at ₹7,293.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas APOLLOHOSP.NS's P/E ratio is 59.21. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to APOLLOHOSP.NS's ROE of +0.21%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to APOLLOHOSP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check APOLLOHOSP.NS's competition here
INDRAMEDCO.BO vs MAXHEALTH.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, MAXHEALTH.NS has a market cap of 936.4B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while MAXHEALTH.NS trades at ₹955.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas MAXHEALTH.NS's P/E ratio is 66.23. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to MAXHEALTH.NS's ROE of +0.15%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to MAXHEALTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check MAXHEALTH.NS's competition here
INDRAMEDCO.BO vs MAXHEALTH.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, MAXHEALTH.BO has a market cap of 935.8B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while MAXHEALTH.BO trades at ₹958.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas MAXHEALTH.BO's P/E ratio is 66.18. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to MAXHEALTH.BO's ROE of +0.15%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to MAXHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check MAXHEALTH.BO's competition here
INDRAMEDCO.BO vs FORTIS.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, FORTIS.NS has a market cap of 600.2B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while FORTIS.NS trades at ₹792.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas FORTIS.NS's P/E ratio is 62.50. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to FORTIS.NS's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to FORTIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check FORTIS.NS's competition here
INDRAMEDCO.BO vs FORTIS.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, FORTIS.BO has a market cap of 599.9B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while FORTIS.BO trades at ₹798.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas FORTIS.BO's P/E ratio is 62.52. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to FORTIS.BO's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to FORTIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check FORTIS.BO's competition here
INDRAMEDCO.BO vs ASTERDM.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, ASTERDM.BO has a market cap of 347.1B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while ASTERDM.BO trades at ₹688.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas ASTERDM.BO's P/E ratio is 105.26. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to ASTERDM.BO's ROE of +0.09%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to ASTERDM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check ASTERDM.BO's competition here
INDRAMEDCO.BO vs ASTERDM.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, ASTERDM.NS has a market cap of 346.3B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while ASTERDM.NS trades at ₹687.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas ASTERDM.NS's P/E ratio is 104.20. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to ASTERDM.NS's ROE of +0.09%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to ASTERDM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check ASTERDM.NS's competition here
INDRAMEDCO.BO vs NH.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, NH.BO has a market cap of 326.1B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while NH.BO trades at ₹1,636.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas NH.BO's P/E ratio is 38.63. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to NH.BO's ROE of +0.21%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to NH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check NH.BO's competition here
INDRAMEDCO.BO vs NH.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, NH.NS has a market cap of 326B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while NH.NS trades at ₹1,632.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas NH.NS's P/E ratio is 41.84. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to NH.NS's ROE of +0.21%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to NH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check NH.NS's competition here
INDRAMEDCO.BO vs MEDANTA.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, MEDANTA.BO has a market cap of 258.4B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while MEDANTA.BO trades at ₹991.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas MEDANTA.BO's P/E ratio is 50.25. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to MEDANTA.BO's ROE of +0.15%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to MEDANTA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check MEDANTA.BO's competition here
INDRAMEDCO.BO vs MEDANTA.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, MEDANTA.NS has a market cap of 258.3B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while MEDANTA.NS trades at ₹987.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas MEDANTA.NS's P/E ratio is 50.24. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to MEDANTA.NS's ROE of +0.15%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to MEDANTA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check MEDANTA.NS's competition here
INDRAMEDCO.BO vs KIMS.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, KIMS.BO has a market cap of 249.1B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while KIMS.BO trades at ₹625.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas KIMS.BO's P/E ratio is 83.01. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to KIMS.BO's ROE of +0.13%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to KIMS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check KIMS.BO's competition here
INDRAMEDCO.BO vs KIMS.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, KIMS.NS has a market cap of 248.7B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while KIMS.NS trades at ₹623.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas KIMS.NS's P/E ratio is 82.76. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to KIMS.NS's ROE of +0.13%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to KIMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check KIMS.NS's competition here
INDRAMEDCO.BO vs RAINBOW.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, RAINBOW.BO has a market cap of 118.1B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while RAINBOW.BO trades at ₹1,173.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas RAINBOW.BO's P/E ratio is 46.07. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to RAINBOW.BO's ROE of +0.18%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to RAINBOW.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check RAINBOW.BO's competition here
INDRAMEDCO.BO vs RAINBOW.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, RAINBOW.NS has a market cap of 118.1B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while RAINBOW.NS trades at ₹1,174.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas RAINBOW.NS's P/E ratio is 46.03. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to RAINBOW.NS's ROE of +0.18%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to RAINBOW.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check RAINBOW.NS's competition here
INDRAMEDCO.BO vs JLHL.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, JLHL.NS has a market cap of 84B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while JLHL.NS trades at ₹1,243.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas JLHL.NS's P/E ratio is 44.44. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to JLHL.NS's ROE of +0.14%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to JLHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check JLHL.NS's competition here
INDRAMEDCO.BO vs JLHL.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, JLHL.BO has a market cap of 83.4B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while JLHL.BO trades at ₹1,244.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas JLHL.BO's P/E ratio is 44.25. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to JLHL.BO's ROE of +0.14%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to JLHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check JLHL.BO's competition here
INDRAMEDCO.BO vs HCG.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, HCG.NS has a market cap of 74.5B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while HCG.NS trades at ₹534.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas HCG.NS's P/E ratio is 394.89. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to HCG.NS's ROE of +0.02%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to HCG.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check HCG.NS's competition here
INDRAMEDCO.BO vs HCG.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, HCG.BO has a market cap of 74.4B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while HCG.BO trades at ₹537.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas HCG.BO's P/E ratio is 394.51. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to HCG.BO's ROE of +0.02%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to HCG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check HCG.BO's competition here
INDRAMEDCO.BO vs YATHARTH.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, YATHARTH.BO has a market cap of 59.5B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while YATHARTH.BO trades at ₹658.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas YATHARTH.BO's P/E ratio is 35.45. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to YATHARTH.BO's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to YATHARTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check YATHARTH.BO's competition here
INDRAMEDCO.BO vs YATHARTH.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, YATHARTH.NS has a market cap of 59.5B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while YATHARTH.NS trades at ₹661.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas YATHARTH.NS's P/E ratio is 35.47. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to YATHARTH.NS's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to YATHARTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check YATHARTH.NS's competition here
INDRAMEDCO.BO vs KOVAI.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, KOVAI.BO has a market cap of 55B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while KOVAI.BO trades at ₹5,067.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas KOVAI.BO's P/E ratio is 23.32. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to KOVAI.BO's ROE of +0.22%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to KOVAI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check KOVAI.BO's competition here
INDRAMEDCO.BO vs KOVAI.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, KOVAI.NS has a market cap of 35.3B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while KOVAI.NS trades at ₹2,581.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas KOVAI.NS's P/E ratio is 20.74. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to KOVAI.NS's ROE of +0.22%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to KOVAI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check KOVAI.NS's competition here
INDRAMEDCO.BO vs INDRAMEDCO.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, INDRAMEDCO.NS has a market cap of 34.1B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while INDRAMEDCO.NS trades at ₹399.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas INDRAMEDCO.NS's P/E ratio is 18.65. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to INDRAMEDCO.NS's ROE of +0.31%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to INDRAMEDCO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check INDRAMEDCO.NS's competition here
INDRAMEDCO.BO vs ARTEMISMED.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, ARTEMISMED.BO has a market cap of 32.5B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while ARTEMISMED.BO trades at ₹220.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas ARTEMISMED.BO's P/E ratio is N/A. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to ARTEMISMED.BO's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to ARTEMISMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check ARTEMISMED.BO's competition here
INDRAMEDCO.BO vs ARTEMISMED.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, ARTEMISMED.NS has a market cap of 32.4B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while ARTEMISMED.NS trades at ₹220.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas ARTEMISMED.NS's P/E ratio is 89.74. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to ARTEMISMED.NS's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to ARTEMISMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check ARTEMISMED.NS's competition here
INDRAMEDCO.BO vs DRAGARWQ.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, DRAGARWQ.BO has a market cap of 22.7B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while DRAGARWQ.BO trades at ₹4,779.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas DRAGARWQ.BO's P/E ratio is 31.92. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to DRAGARWQ.BO's ROE of +0.30%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to DRAGARWQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check DRAGARWQ.BO's competition here
INDRAMEDCO.BO vs SHALBY.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, SHALBY.BO has a market cap of 13.6B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while SHALBY.BO trades at ₹139.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas SHALBY.BO's P/E ratio is 162.63. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to SHALBY.BO's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to SHALBY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check SHALBY.BO's competition here
INDRAMEDCO.BO vs SHALBY.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, SHALBY.NS has a market cap of 13.6B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while SHALBY.NS trades at ₹138.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas SHALBY.NS's P/E ratio is 164.68. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to SHALBY.NS's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to SHALBY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check SHALBY.NS's competition here
INDRAMEDCO.BO vs KMCSHIL.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, KMCSHIL.BO has a market cap of 12.8B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while KMCSHIL.BO trades at ₹81.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas KMCSHIL.BO's P/E ratio is 35.16. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to KMCSHIL.BO's ROE of +0.22%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to KMCSHIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check KMCSHIL.BO's competition here
INDRAMEDCO.BO vs MAXINDIA.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, MAXINDIA.BO has a market cap of 9.2B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while MAXINDIA.BO trades at ₹213.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas MAXINDIA.BO's P/E ratio is -3560.83. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to MAXINDIA.BO's ROE of +0.15%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to MAXINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check MAXINDIA.BO's competition here
INDRAMEDCO.BO vs MAXIND.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, MAXIND.NS has a market cap of 6.5B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while MAXIND.NS trades at ₹140.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas MAXIND.NS's P/E ratio is -4.13. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to MAXIND.NS's ROE of -0.36%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to MAXIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check MAXIND.NS's competition here
INDRAMEDCO.BO vs UNIHEALTH.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, UNIHEALTH.NS has a market cap of 5.6B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while UNIHEALTH.NS trades at ₹380.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas UNIHEALTH.NS's P/E ratio is 36.87. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to UNIHEALTH.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to UNIHEALTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check UNIHEALTH.NS's competition here
INDRAMEDCO.BO vs ASARFI.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, ASARFI.BO has a market cap of 3.3B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while ASARFI.BO trades at ₹176.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas ASARFI.BO's P/E ratio is 20.40. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to ASARFI.BO's ROE of +0.14%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to ASARFI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check ASARFI.BO's competition here
INDRAMEDCO.BO vs LOTUSEYE.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, LOTUSEYE.BO has a market cap of 2.1B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while LOTUSEYE.BO trades at ₹102.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas LOTUSEYE.BO's P/E ratio is 316.72. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to LOTUSEYE.BO's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to LOTUSEYE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check LOTUSEYE.BO's competition here
INDRAMEDCO.BO vs LOTUSEYE.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, LOTUSEYE.NS has a market cap of 2B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while LOTUSEYE.NS trades at ₹102.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas LOTUSEYE.NS's P/E ratio is 306.94. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to LOTUSEYE.NS's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to LOTUSEYE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check LOTUSEYE.NS's competition here
INDRAMEDCO.BO vs LEHIL.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, LEHIL.BO has a market cap of 1.9B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while LEHIL.BO trades at ₹89.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas LEHIL.BO's P/E ratio is -315.00. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to LEHIL.BO's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to LEHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check LEHIL.BO's competition here
INDRAMEDCO.BO vs MADHAVBAUG.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, MADHAVBAUG.NS has a market cap of 1.8B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while MADHAVBAUG.NS trades at ₹164.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas MADHAVBAUG.NS's P/E ratio is 21.55. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to MADHAVBAUG.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to MADHAVBAUG.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check MADHAVBAUG.NS's competition here
INDRAMEDCO.BO vs AASHKA.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, AASHKA.BO has a market cap of 1.4B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while AASHKA.BO trades at ₹59.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas AASHKA.BO's P/E ratio is 56.73. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to AASHKA.BO's ROE of +0.02%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to AASHKA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check AASHKA.BO's competition here
INDRAMEDCO.BO vs JSTL.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, JSTL.BO has a market cap of 1B. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while JSTL.BO trades at ₹63.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas JSTL.BO's P/E ratio is -50.39. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to JSTL.BO's ROE of -0.06%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to JSTL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check JSTL.BO's competition here
INDRAMEDCO.BO vs MAITREYA.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, MAITREYA.NS has a market cap of 971.2M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while MAITREYA.NS trades at ₹178.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas MAITREYA.NS's P/E ratio is 27.77. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to MAITREYA.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to MAITREYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check MAITREYA.NS's competition here
INDRAMEDCO.BO vs FORTISMLR.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, FORTISMLR.BO has a market cap of 781.3M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while FORTISMLR.BO trades at ₹45.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas FORTISMLR.BO's P/E ratio is 17.23. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to FORTISMLR.BO's ROE of +0.15%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to FORTISMLR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check FORTISMLR.BO's competition here
INDRAMEDCO.BO vs ASPIRA.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, ASPIRA.BO has a market cap of 574.9M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while ASPIRA.BO trades at ₹55.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas ASPIRA.BO's P/E ratio is 40.47. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to ASPIRA.BO's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to ASPIRA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check ASPIRA.BO's competition here
INDRAMEDCO.BO vs SANGANI.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, SANGANI.NS has a market cap of 535.9M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while SANGANI.NS trades at ₹40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas SANGANI.NS's P/E ratio is 20.69. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to SANGANI.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to SANGANI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check SANGANI.NS's competition here
INDRAMEDCO.BO vs MEDINOV.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, MEDINOV.BO has a market cap of 433.7M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while MEDINOV.BO trades at ₹43.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas MEDINOV.BO's P/E ratio is 20.21. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to MEDINOV.BO's ROE of -1.80%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to MEDINOV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check MEDINOV.BO's competition here
INDRAMEDCO.BO vs NGIND.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, NGIND.BO has a market cap of 427.5M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while NGIND.BO trades at ₹135.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas NGIND.BO's P/E ratio is -30.90. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to NGIND.BO's ROE of -0.04%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to NGIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check NGIND.BO's competition here
INDRAMEDCO.BO vs AATMAJ.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, AATMAJ.NS has a market cap of 414.7M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while AATMAJ.NS trades at ₹20.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas AATMAJ.NS's P/E ratio is 47.05. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to AATMAJ.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to AATMAJ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check AATMAJ.NS's competition here
INDRAMEDCO.BO vs SML.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, SML.BO has a market cap of 299.5M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while SML.BO trades at ₹70.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas SML.BO's P/E ratio is -15.00. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to SML.BO's ROE of -2.04%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to SML.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check SML.BO's competition here
INDRAMEDCO.BO vs KKSHL.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, KKSHL.BO has a market cap of 250.9M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while KKSHL.BO trades at ₹36.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas KKSHL.BO's P/E ratio is -24.40. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to KKSHL.BO's ROE of -0.02%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to KKSHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check KKSHL.BO's competition here
INDRAMEDCO.BO vs CMMHOSP.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, CMMHOSP.BO has a market cap of 246.5M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while CMMHOSP.BO trades at ₹32.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas CMMHOSP.BO's P/E ratio is -31.74. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to CMMHOSP.BO's ROE of +0.42%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to CMMHOSP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check CMMHOSP.BO's competition here
INDRAMEDCO.BO vs TEJNAKSH.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, TEJNAKSH.BO has a market cap of 242.3M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while TEJNAKSH.BO trades at ₹12.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas TEJNAKSH.BO's P/E ratio is 17.54. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to TEJNAKSH.BO's ROE of +0.05%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to TEJNAKSH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check TEJNAKSH.BO's competition here
INDRAMEDCO.BO vs NIDAN.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, NIDAN.NS has a market cap of 177.2M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while NIDAN.NS trades at ₹13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas NIDAN.NS's P/E ratio is 8.98. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to NIDAN.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to NIDAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check NIDAN.NS's competition here
INDRAMEDCO.BO vs GLHRL.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, GLHRL.BO has a market cap of 143.4M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while GLHRL.BO trades at ₹13.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas GLHRL.BO's P/E ratio is -6.07. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to GLHRL.BO's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to GLHRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check GLHRL.BO's competition here
INDRAMEDCO.BO vs FAMILYCARE.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, FAMILYCARE.BO has a market cap of 141.5M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while FAMILYCARE.BO trades at ₹2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas FAMILYCARE.BO's P/E ratio is -2.70. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to FAMILYCARE.BO's ROE of -0.43%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to FAMILYCARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check FAMILYCARE.BO's competition here
INDRAMEDCO.BO vs ZDHJERK.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, ZDHJERK.BO has a market cap of 103M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while ZDHJERK.BO trades at ₹26.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas ZDHJERK.BO's P/E ratio is 83.80. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to ZDHJERK.BO's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to ZDHJERK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check ZDHJERK.BO's competition here
INDRAMEDCO.BO vs LOOKS.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, LOOKS.BO has a market cap of 69.6M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while LOOKS.BO trades at ₹6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas LOOKS.BO's P/E ratio is 33.15. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to LOOKS.BO's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to LOOKS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check LOOKS.BO's competition here
INDRAMEDCO.BO vs DLCL.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, DLCL.BO has a market cap of 64.2M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while DLCL.BO trades at ₹14.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas DLCL.BO's P/E ratio is 19.23. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to DLCL.BO's ROE of +0.04%. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to DLCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check DLCL.BO's competition here
INDRAMEDCO.BO vs GIANLIFE.BO Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, GIANLIFE.BO has a market cap of 63.5M. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while GIANLIFE.BO trades at ₹6.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas GIANLIFE.BO's P/E ratio is -6.53. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to GIANLIFE.BO's ROE of -0.05%. Regarding short-term risk, INDRAMEDCO.BO is less volatile compared to GIANLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check GIANLIFE.BO's competition here
INDRAMEDCO.BO vs NEPHROCARE-ST.NS Comparison April 2026
INDRAMEDCO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.BO stands at 34.1B. In comparison, NEPHROCARE-ST.NS has a market cap of 0. Regarding current trading prices, INDRAMEDCO.BO is priced at ₹400.00, while NEPHROCARE-ST.NS trades at ₹128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.BO currently has a P/E ratio of 18.62, whereas NEPHROCARE-ST.NS's P/E ratio is N/A. In terms of profitability, INDRAMEDCO.BO's ROE is +0.31%, compared to NEPHROCARE-ST.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.BO is more volatile compared to NEPHROCARE-ST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.BO.Check NEPHROCARE-ST.NS's competition here